search
Back to results

Cost Effectiveness in Alveolar Bone Grafting in Patients With Cleft Lip and Palate

Primary Purpose

Cleft Lip and Palate

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Intervention group (DBM/BMP)
Control group(autologous ICBG)
Sponsored by
The University of Texas Health Science Center, Houston
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Cleft Lip and Palate focused on measuring alveolar bone graft, Bone Morphogenic Protein, Demineralized Bone Matrix, cleft lip

Eligibility Criteria

6 Years - 15 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient with CLP(unilateral or bilateral)
  • Radiographically evident open bone defect of the alveolus
  • Dentition evaluated by orthodontist and cleared for ABG surgery

Exclusion Criteria:

  • Patients without CLP
  • Previous failed repair of alveolar cleft
  • Patients who have previously undergone successful ABG
  • Patients without an alveolar defect
  • Patients whose parents refuse to consent to randomization
  • Patients who have a syndromic CLP

Sites / Locations

  • The University of Texas Health Science Center at HoustonRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intervention group (DBM/BMP)

Control group(autologous ICBG)

Arm Description

Patient undergoes Alveolar bone graft with DBM/BMP

Patient undergoes Alveolar Bone Graft with Iliac Crest Bone graft.

Outcomes

Primary Outcome Measures

Health system costs per successful bone graft.
Health system costs will be reported as the total sum of all costs including incremental surgeon time costs, hospital costs, revision costs, and additional outpatient costs for clinic or ER visits. Bone graft success be defined as no need for a repeat bone graft, as well as by assessment by blinded orthodontist evaluations of the Post op Cone beam computed tomography(CBCT).

Secondary Outcome Measures

Graft Success
Graft success as indicated by number of patients that did not have exposure of graft as assessed by post op CBCT
Infection
Graft success as indicated by number of patients that had no graft infection as assessed by post op CBCT
Fistula Recurrence
Graft success as indicated by number of patients that had no recurrence of oronasal fistula as assessed by post op CBCT
Rate of Revision ABG
Graft success as indicated by number of patients that had no no need for repeat bone graft as assessed by post op CBCT
Operative Time
Total time for operation
Anesthesia Time
total time of anesthesia
Post Operative Pain Scores
Change in pain as assessed by the numeric Rating Scale(NRS) for pain. The NRS total score ranges form 0(no hurt) to 10(hurts worst)
Pain Medication Usage
Total dose of post-operative narcotics used
Post Op Fever
Number of patients with the post operative complication fever
Drainage from Fistula
Number of patients with the post operative complication drainage from donor site or alveolar site
Post Op ER Visits
Number of patients with the post operative complication ER or primary care visits

Full Information

First Posted
January 15, 2020
Last Updated
June 2, 2022
Sponsor
The University of Texas Health Science Center, Houston
search

1. Study Identification

Unique Protocol Identification Number
NCT04234971
Brief Title
Cost Effectiveness in Alveolar Bone Grafting in Patients With Cleft Lip and Palate
Official Title
Cost Effectiveness in Alveolar Bone Grafting in Patients With Cleft Lip and Palate: A Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 14, 2021 (Actual)
Primary Completion Date
January 1, 2024 (Anticipated)
Study Completion Date
January 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The University of Texas Health Science Center, Houston

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this trial is to evaluate if the use of Bone Morphogenic Protein(BMP)/Demineralized Bone Matrix (DBM) versus the use of autologous Iliac Crest Bone Graft (ICBG) will result in an increase in total cost effectiveness for patients undergoing alveolar bone graft (ABG) for Cleft Lip and Palate (CLP) and to see if patients who are treated with DBM/BMP will have reduced post-operative pain scores,reduced operative times,and similar rates of bone healing compared to conventional ICBG.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cleft Lip and Palate
Keywords
alveolar bone graft, Bone Morphogenic Protein, Demineralized Bone Matrix, cleft lip

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
To prevent surgeon bias in operative time and therefore cost, randomization assignments will be concealed at the beginning of surgery. The surgeon will start with closure of the oronasal fistula first. Once that is completed, the envelope will be opened and reveal the type of bone graft selected. The surgeon will then either harvest the additional ICBG or open the packets for the DBM/BMP and pack the selected type of bone into the alveolus. Outcomes assessor including orthodontist and clinical research evaluator will be blinded to treatment arms.
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention group (DBM/BMP)
Arm Type
Experimental
Arm Description
Patient undergoes Alveolar bone graft with DBM/BMP
Arm Title
Control group(autologous ICBG)
Arm Type
Active Comparator
Arm Description
Patient undergoes Alveolar Bone Graft with Iliac Crest Bone graft.
Intervention Type
Drug
Intervention Name(s)
Intervention group (DBM/BMP)
Intervention Description
All patients will undergo a standard procedure for exposure of the cleft alveolar defect and closure of all oronasal fistulae. After induction of general anesthesia, the patient will be intubated with an oral ray tube and prepped and draped in sterile fashion. Pre-operative antibiotics will be given to cover oral flora (i.e. Unasyn or clindamycin if penicillin allergy exists). The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed. For the treatment group, 10cc of crushed DBM will be mixed with the micro-sized sponge of rh-BMP-2 (Infuse Bone Graft, Medronic, Minneapolis, MN). The sponge and DBM will then be packed into the defect to completely fill the bony space (FIGURE 3). The anterior mucosa will then be closed.
Intervention Type
Drug
Intervention Name(s)
Control group(autologous ICBG)
Intervention Description
The patient will be induced with anesthesia, prepped, and draped. The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed.In the control group, the ICBG will be harvested percutaneously using the Accumed bone graft harvesting system. Briefly, an incision will be made in iliac crest and drill bit inserted. Multiple passes of the drill be used to harvest as much autograft bone as possible from the cancellous region of the iliac crest.Following harvest, fibrin glue will be instilled for hemostasis and a Ropivicaine On-Q pain pump inserted for post-operative pain control. The harvest bone graft will be packed into the alveolar defect in a similar fashion and the mucosa closed anteriorly.
Primary Outcome Measure Information:
Title
Health system costs per successful bone graft.
Description
Health system costs will be reported as the total sum of all costs including incremental surgeon time costs, hospital costs, revision costs, and additional outpatient costs for clinic or ER visits. Bone graft success be defined as no need for a repeat bone graft, as well as by assessment by blinded orthodontist evaluations of the Post op Cone beam computed tomography(CBCT).
Time Frame
One year post graft
Secondary Outcome Measure Information:
Title
Graft Success
Description
Graft success as indicated by number of patients that did not have exposure of graft as assessed by post op CBCT
Time Frame
3 months post graft
Title
Infection
Description
Graft success as indicated by number of patients that had no graft infection as assessed by post op CBCT
Time Frame
3 months post graft
Title
Fistula Recurrence
Description
Graft success as indicated by number of patients that had no recurrence of oronasal fistula as assessed by post op CBCT
Time Frame
3 months post graft
Title
Rate of Revision ABG
Description
Graft success as indicated by number of patients that had no no need for repeat bone graft as assessed by post op CBCT
Time Frame
3 months post graft
Title
Operative Time
Description
Total time for operation
Time Frame
1 day
Title
Anesthesia Time
Description
total time of anesthesia
Time Frame
1 day
Title
Post Operative Pain Scores
Description
Change in pain as assessed by the numeric Rating Scale(NRS) for pain. The NRS total score ranges form 0(no hurt) to 10(hurts worst)
Time Frame
1 week post operatively
Title
Pain Medication Usage
Description
Total dose of post-operative narcotics used
Time Frame
1 week post operatively
Title
Post Op Fever
Description
Number of patients with the post operative complication fever
Time Frame
3 months
Title
Drainage from Fistula
Description
Number of patients with the post operative complication drainage from donor site or alveolar site
Time Frame
3 months
Title
Post Op ER Visits
Description
Number of patients with the post operative complication ER or primary care visits
Time Frame
3 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient with CLP(unilateral or bilateral) Radiographically evident open bone defect of the alveolus Dentition evaluated by orthodontist and cleared for ABG surgery Exclusion Criteria: Patients without CLP Previous failed repair of alveolar cleft Patients who have previously undergone successful ABG Patients without an alveolar defect Patients whose parents refuse to consent to randomization Patients who have a syndromic CLP
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Matthew Greives, MD
Phone
(713) 500-7275
Email
Matthew.R.Greives@uth.tmc.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Yvette Boyd
Phone
713-500-7311
Email
Yvette.J.Boyd@uth.tmc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Matthew Greives, MD
Organizational Affiliation
The University of Texas Health Science Center, Houston
Official's Role
Principal Investigator
Facility Information:
Facility Name
The University of Texas Health Science Center at Houston
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matthew Greives, MD
Phone
713-500-7275
Email
Matthew.R.Greives@uth.tmc.edu
First Name & Middle Initial & Last Name & Degree
Yvette Boyd
Phone
713-500-7311
Email
Yvette.J.boyd@uth.tmc.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Cost Effectiveness in Alveolar Bone Grafting in Patients With Cleft Lip and Palate

We'll reach out to this number within 24 hrs